BrainAurora Medical Technology Limited announced two milestones underscoring its dual focus on artificial-intelligence (AI) R&D and evidence-based digital therapeutics.\n\nKey event 1: Runner-up in national AI model contest\n• BrainAurora’s self-developed BrainAuGPT cognitive deep-reasoning large model won second place in the “Artificial Intelligence +” New Scenario Track of the 3rd Xiongan Vertical Large Model (Intelligent Agent) Application Competition. The event drew more than 700 domestic and international AI projects, with 52 finalists.\n• The company’s entry leveraged three proprietary technologies—graph-structured behavioural data mining, second-order knowledge-representation fine-tuning, and a hybrid Monte Carlo tree-search/entropy-enhanced de-hallucination approach—to build a “cloud-edge-end” assessment system and personalised AI intervention platform.\n• Separately, a subsidiary project was named a “Typical Case of Artificial Intelligence Empowering Scenario Application (2026)” at the 2026 Global Digital Economy Conference.\n\nKey event 2: Peer-reviewed validation of digital therapeutic efficacy\n• A secondary analysis of a multicentre, double-blind, randomised clinical trial (NCT05735041) using BrainAurora’s adaptive cognitive-training product was published in Alzheimer’s Research & Therapy (Impact Factor 8.9, JCR Q1).\n• The study enrolled 185 coronary heart disease patients with mild cognitive impairment. After 12 weeks of training, participants showed statistically significant increases in functional connectivity within the parietal memory and contextual association networks and greater grey-matter volume in the right precuneus and parahippocampal cortex (p-values 0.028–0.048).\n• Enhanced connectivity between the right parietal memory network and cingulo-opercular network correlated negatively with systolic blood pressure and pulse pressure; mediation analysis indicated an indirect effect of 0.62 (p = 0.040) on pulse-pressure reduction, suggesting interplay along the “brain-heart axis.”\n\nStrategic implications\nThe dual achievements highlight BrainAurora’s competitive edge in medical-grade large-language-model innovation and reinforce its leadership in cognitive-impairment digital therapeutics. Validation from national-level AI competitions and high-impact clinical publication strengthens the company’s positioning for future product deployment and supports its long-term growth strategy.